KalVista Pharmaceuticals, Inc. Q4 Loss increases, but beats estimates

KalVista Pharmaceuticals, Inc. (KALV) revealed Loss for its fourth quarter that increased from last year but beat the Street estimates.

The company's bottom line totaled -$24.11 million, or -$0.98 per share. This compares with -$14.95 million, or -$0.65 per share, in last year's fourth quarter.

Analysts on average had expected the company to earn -$1.09 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

KalVista Pharmaceuticals, Inc. earnings at a glance (GAAP) :

-Earnings (Q4): -$24.11 Mln. vs. -$14.95 Mln. last year.
-EPS (Q4): -$0.98 vs. -$0.65 last year.
-Analyst Estimate: -$1.09

For comments and feedback contact: editorial@rttnews.com

Follow RTT